Evidence map›Paper›PMID 36245713›Full record

ReviewFrontiers in pediatrics2022

Applications of next generation sequencing in the screening and diagnosis of thalassemia: A mini-review.

Syahirah Amnani Suhaimi, Ihsan Nazurah Zulkipli, Hazim Ghani, Mas Rina Wati Abdul-Hamid

Abstract readReview
In one paragraph

Review in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Syahirah Amnani SuhaimiPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei.
Ihsan Nazurah ZulkipliPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei.
Hazim GhaniPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei.
Mas Rina Wati Abdul-HamidPAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thalassemias are a group of inherited blood disorders that affects 5-7% of the world population. Comprehensive screening strategies are essential for the management and prevention of this disorder. Today, many clinical and research laboratories have widely utilized next-generation sequencing (NGS) technologies to identify diseases, from germline and somatic disorders to infectious diseases. Yet, NGS application in thalassemia is limited and has just recently surfaced due to current demands in seeking alternative DNA screening tools that are more efficient, versatile, and cost-effective. This review aims to understand the several aspects of NGS technology, including its most current and expanding uses, advantages, and limitations, along with the issues and solutions related to its integration into routine screening and diagnosis of thalassemias. Hitherto, NGS has been a groundbreaking technology that offers tremendous improvements as a diagnostic tool for thalassemia in terms of its higher throughput, accuracy, and adaptability. The superiority of NGS in detecting rare variants, solving complex hematological problems, and providing non-invasive alternatives to neonatal diagnosis cannot be overlooked. However, several pitfalls still preclude its use as a stand-alone technique over conventional methods.

Indexed as

NGStargeted sequencingthalassemia programsWESWGSα-thalassemiaβ-thalassemia

Identifiers

PMID36245713
PMCPMC9557073

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.